Intuitive Surgical Company Profile (NASDAQ:ISRG)

Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."

Intuitive Surgical, Inc. (NASDAQ:ISRG) issued its quarterly earnings data on Thursday, July, 20th. The company reported $5.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.79 by $0.16. The business earned $756.20 million during the quarter, compared to analyst estimates of $724.51 million. Intuitive Surgical had a net margin of 28.44% and a return on equity of 15.51%. The firm's quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the business earned $5.62 EPS. View Intuitive Surgical's Earnings History.

Intuitive Surgical is scheduled to release their next quarterly earnings announcement on Monday, October, 16th 2017. View Earnings Estimates for Intuitive Surgical.

17 brokers have issued 1 year target prices for Intuitive Surgical's stock. Their forecasts range from $675.00 to $1,100.00. On average, they anticipate Intuitive Surgical's stock price to reach $944.80 in the next year. View Analyst Ratings for Intuitive Surgical.

Here are some recent quotes from research analysts about Intuitive Surgical stock:

• 1. Cantor Fitzgerald analysts commented, "Procedure growth: Guidance for 2017 procedure growth appears to be conservative. ISRG had 17% procedure growth in the 1H and is guiding to 14-15% procedure growth for 2017, implying 11-13% procedure growth in the 2H. The first-half procedure growth came in above expectations, as gynecology (grew in low single digits) and urology (grew in mid-to-high single digits) and China (grew by well over 25%) outpaced expectations. Second-half guidance assumes slower growth in gynecology, urology, and China, one less selling day in 3Q, and lower growth in Japan due to a lack of reimbursement." (7/21/2017)
• 2. According to Zacks Investment Research, "Over the last three months, Intuitive Surgical was trading consistently ahead of the broader industry. While a stellar first-quarter 2017 result was a major market sentiment booster, the company gained significantly on the CE Mark approval for da Vinci X in Europe. The stock has got a further boost on the recent U.S. FDA approval of the same. A positive outlook for the coming quarters also raises our confidence in the stock. Further, incremental spending on product development and higher investments in international markets are prudent moves that are likely to drive long-term growth. The company is also expected to enhance its organizational capabilities and gain prominence in the markets of Europe and Asia. However, the da Vinci Surgical System has a long sale and purchase order cycle which might act against the company. In fact, the stock looks a tad expensive, adding to our concerns." (6/20/2017)

Some companies that are related to Intuitive Surgical include Danaher Corporation (DHR), Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY) and Quidel Corporation (QDEL).

Intuitive Surgical's management team includes the folowing people:

• Lonnie M. Smith, Independent Chairman of the Board
• Gary S. Guthart Ph.D., President, Chief Executive Officer, Director
• Marshall L. Mohr, Chief Financial Officer, Senior Vice President
• Salvatore J. Brogna, Executive Vice President - Product Operations
• David J. Rosa, Executive Vice President, Chief Commercial Officer
• Mark J. Meltzer, Senior Vice President, Chief Compliance Officer, General Counsel
• Myriam J. Curet M.D., Senior Vice President, Chief Medical Officer
• Jamie E. Samath, Vice President, Corporate Controller, and Principal Accounting Officer
• Alan J. Levy Ph.D., Lead Independent Director
• Craig H. Barratt Ph.D., Independent Director

Intuitive Surgical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Chevy Chase Trust Holdings Inc. (0.16%), Bank of Montreal Can (0.11%), Manning & Napier Advisors LLC (0.11%), Gateway Investment Advisers LLC (0.10%), National Pension Service (0.09%) and APG Asset Management N.V. (0.08%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Eric H Halvorson, Gary S Guthart, George Stalk Jr, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.

Intuitive Surgical's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Factory Mutual Insurance Co., Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Rothschild Investment Corp IL, OLD National Bancorp IN, Quantitative Systematic Strategies LLC and Oregon Public Employees Retirement Fund. Company insiders that have sold Intuitive Surgical stock in the last year include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.

Intuitive Surgical's stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Assenagon Asset Management S.A., National Pension Service, Chevy Chase Trust Holdings Inc., Aperio Group LLC, Deane Retirement Strategies Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Intuitive Surgical.

Shares of Intuitive Surgical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intuitive Surgical stock can currently be purchased for approximately $927.47.